These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 38928347)
1. An SNP Marker Predicts Colorectal Cancer Outcomes with 5-Fluorouracil-Based Adjuvant Chemotherapy Post-Resection. Chien H; Chu YD; Hsu YP; Yeh CT; Lai MW; Chang ML; Lim SN; Chen CW; Lin WR Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928347 [TBL] [Abstract][Full Text] [Related]
2. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048 [TBL] [Abstract][Full Text] [Related]
3. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer. Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222 [TBL] [Abstract][Full Text] [Related]
4. GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy. Wang Z; Jiang B; Chen L; Di J; Cui M; Liu M; Ma Y; Yang H; Xing J; Zhang C; Yao Z; Zhang N; Dong B; Ji J; Su X J Transl Med; 2014 Jan; 12():15. PubMed ID: 24444035 [TBL] [Abstract][Full Text] [Related]
5. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967 [TBL] [Abstract][Full Text] [Related]
6. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer. Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901 [TBL] [Abstract][Full Text] [Related]
7. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit. Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060 [TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer]. Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867 [TBL] [Abstract][Full Text] [Related]
9. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513 [TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944 [TBL] [Abstract][Full Text] [Related]
11. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer. Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of 5-fluorouracil metabolic enzymes as predictors of response to adjuvant chemotherapy outcomes in patients with stage II/III colorectal cancer: a decision-curve analysis. Shigeta K; Ishii Y; Hasegawa H; Okabayashi K; Kitagawa Y World J Surg; 2014 Dec; 38(12):3248-56. PubMed ID: 25167895 [TBL] [Abstract][Full Text] [Related]
13. Associations between genetic polymorphisms of epidermal growth factor receptor (EGFR) and survival of colorectal cancer (CRC) patients treated with 5-fluorouracil-based chemotherapy. Lai CY; Sung FC; Hsieh LL; Tang R; Chiou HY; Wu FY; Yeh CC Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S599-606. PubMed ID: 23800895 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062 [TBL] [Abstract][Full Text] [Related]
15. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096 [TBL] [Abstract][Full Text] [Related]
16. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179 [TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227 [TBL] [Abstract][Full Text] [Related]
18. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Liang KH; Lin CC; Yeh CT Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146 [TBL] [Abstract][Full Text] [Related]
19. Genetic variations in the HIF1A gene modulate response to adjuvant chemotherapy after surgery in patients with colorectal cancer. Zhang Y; Wang P; Zhou XC; Bao GQ; Lyu ZM; Liu XN; Wan SG; He XL; Huang QC Asian Pac J Cancer Prev; 2014; 15(11):4637-42. PubMed ID: 24969897 [TBL] [Abstract][Full Text] [Related]